These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 37527044)

  • 1. Clinical significance of atypical
    Gossili F; Almasi CE; Zacho HD
    Hell J Nucl Med; 2023; 26(2):94-98. PubMed ID: 37527044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gallium-68 DOTATOC PET/CT in vivo characterization of somatostatin receptor expression in the prostate.
    Todorović-Tirnanić MV; Gajić MM; Obradović VB; Baum RP
    Cancer Biother Radiopharm; 2014 Apr; 29(3):108-15. PubMed ID: 24450327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT.
    Luboldt W; Zöphel K; Wunderlich G; Abramyuk A; Luboldt HJ; Kotzerke J
    Mol Imaging Biol; 2010; 12(1):78-84. PubMed ID: 19421819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of
    Lodge MA; Solnes LB; Chaudhry MA; Wahl RL
    Mol Imaging Biol; 2021 Oct; 23(5):766-774. PubMed ID: 33829361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of
    Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
    Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?
    Al-Ibraheem A; Bundschuh RA; Notni J; Buck A; Winter A; Wester HJ; Schwaiger M; Scheidhauer K
    Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):2005-13. PubMed ID: 21792572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency of thyroid incidental findings and risk of malignancy detected by
    Gossili F; Petersen LJ; Zacho HD
    Hell J Nucl Med; 2020; 23(3):240-245. PubMed ID: 33306753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.
    Miederer M; Seidl S; Buck A; Scheidhauer K; Wester HJ; Schwaiger M; Perren A
    Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):48-52. PubMed ID: 18807033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
    Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
    Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-Head Comparison of
    Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of "Incidentalomas" on Brain and Body
    Umana GE; Ferini G; Harikar MM; Venkataram T; Costanzo R; Scalia G; Palmisciano P; Brunasso L; Paolini F; Sciortino A; Maugeri R; Crea A; Barone F; Inserra F; DA Ros V; Cuttone G; Corsale G; Cristaudo C; Cosentino S; Sabini MG; Ippolito M
    Anticancer Res; 2022 Dec; 42(12):5867-5873. PubMed ID: 36456146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
    Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
    Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from
    Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
    BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
    Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
    Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.